Clinical Trials of Mesenchymal Stem Cells for the Treatment of COVID 19


Cite item

Full Text

Abstract

Mesenchymal Stem Cells (MSCs) are being investigated as a treatment for a novel viral disease owing to their immunomodulatory, anti-inflammatory, tissue repair and regeneration characteristics, however, the exact processes are unknown. MSC therapy was found to be effective in lowering immune system overactivation and increasing endogenous healing after SARS-CoV-2 infection by improving the pulmonary microenvironment. Many studies on mesenchymal stem cells have been undertaken concurrently, and we may help speed up the effectiveness of these studies by collecting and statistically analyzing data from them. Based on clinical trial information found on clinicaltrials. gov and on 16 November 2020, which includes 63 clinical trials in the field of patient treatment with COVID-19 using MSCs, according to the trend of increasing studies in this field, and with the help of meta-analysis studies, it is possible to hope that the promise of MSCs will one day be realized. The potential therapeutic applications of MSCs for COVID-19 are investigated in this study.

About the authors

Elham Zendedel

Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Shahrekord University of Medical Sciences

Email: info@benthamscience.net

Lobat Tayebi

, Marquett University School of Dentistry

Email: info@benthamscience.net

Mohammad Nikbakht

Department of Medical Biotechnology, School of Advanced Technologies, Shahrekord University of Medical Sciences

Email: info@benthamscience.net

Elham Hasanzadeh

Immunogenetics Research Center, Department of Tissue Engineering & Regenerative Medicine, School of Advanced Technologies in Medicine, Mazandaran University of Medical Sciences

Author for correspondence.
Email: info@benthamscience.net

Shiva Asadpour

Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Shahrekord University of Medical Sciences

Author for correspondence.
Email: info@benthamscience.net

References

  1. Hassan SA, Sheikh FN, Jamal S, Ezeh JK, Akhtar A. Coronavirus (COVID-19): a review of clinical features, diagnosis, and treatment. Cureus 2020; 12(3): e7355. doi: 10.7759/cureus.7355 PMID: 32328367
  2. Hasanzadeh E, Rafati A, Tamijani SMSH, Rafaiee R, Golchin A, Abasi M. The Role of Advanced Technologies against COVID-19: Prevention, Detection, and Treatments. Curr Stem Cell Res Ther 2023; 18(6): 800-28. doi: 10.2174/1574888X18666221221123505 PMID: 36545723
  3. Kannan S, Shaik Syed Ali P, Sheeza A, Hemalatha K. COVID-19 (Novel Coronavirus 2019) - recent trends. Eur Rev Med Pharmacol Sci 2020; 24(4): 2006-11. PMID: 32141569
  4. Marra MA, Jones SJM, Astell CR, et al. The Genome sequence of the SARS-associated coronavirus. Science 2003; 300(5624): 1399-404. doi: 10.1126/science.1085953 PMID: 12730501
  5. Cooper TJ, Woodward BL, Alom S, Harky A. Coronavirus disease 2019 (COVID-19) outcomes in HIV/AIDS patients: a systematic review. HIV Med 2020; 21(9): 567-77. doi: 10.1111/hiv.12911 PMID: 32671970
  6. Kumar D, Malviya R, Sharma PK. Corona virus: a review of COVID-19. Eurasian Journal of Medicine and Oncology 2020; 4(1): 8-25.
  7. Chen L, Lou J, Bai Y, Wang M. COVID-19 disease with positive fecal and negative pharyngeal and sputum viral tests. Am J Gastroenterol 2020; 115(5): 790. doi: 10.14309/ajg.0000000000000610 PMID: 32205644
  8. Team E. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China. China CDC weekly 2020; 2(8): 113.
  9. Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: Immunology and treatment options. Clin Immunol 2020; 215: 108448. doi: 10.1016/j.clim.2020.108448 PMID: 32353634
  10. Rajnik M, Cascella M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). Treasure Island (FL): StatPearls 2021.
  11. Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis 2020; 11(2): 216-28. doi: 10.14336/AD.2020.0228 PMID: 32257537
  12. Enderami SE, Kia V, Eshaghi-Gorji R, et al. Mesenchymal Stromal Cells and their EVs as Potential Leads for SARSCoV2 Treatment. Curr Stem Cell Res Ther 2023; 18(1): 35-53. doi: 10.2174/1574888X17666220426115831 PMID: 35473518
  13. Walter J, Ware LB, Matthay MA. Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis. Lancet Respir Med 2014; 2(12): 1016-26. doi: 10.1016/S2213-2600(14)70217-6 PMID: 25465643
  14. Al Naem M, Bourebaba L, Kucharczyk K, Röcken M, Marycz K. Therapeutic mesenchymal stromal stem cells: Isolation, characterization and role in equine regenerative medicine and metabolic disorders. Stem Cell Rev Rep 2020; 16(2): 301-22. doi: 10.1007/s12015-019-09932-0 PMID: 31797146
  15. Hasanzadeh E, Mahmoodi N, Basiri A, et al. Proanthocyanidin as a crosslinking agent for fibrin, collagen hydrogels and their composites with decellularized Wharton’s-jelly-extract for tissue engineering applications. J Bioact Compat Polym 2020; 35(6): 554-71. doi: 10.1177/0883911520956252
  16. Golchin A, Seyedjafari E, Ardeshirylajimi A. Mesenchymal stem cell therapy for COVID-19: present or future. Stem Cell Rev Rep 2020; 16(3): 427-33. doi: 10.1007/s12015-020-09973-w PMID: 32281052
  17. Rogers CJ, Harman RJ, Bunnell BA, et al. Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients. J Transl Med 2020; 18(1): 203. doi: 10.1186/s12967-020-02380-2 PMID: 32423449
  18. Ellison-Hughes GM, Colley L, O’Brien KA, Roberts KA, Agbaedeng TA, Ross MD. The role of MSC therapy in attenuating the damaging effects of the cytokine storm induced by COVID-19 on the heart and cardiovascular system. Front Cardiovasc Med 2020; 7: 602183. doi: 10.3389/fcvm.2020.602183 PMID: 33363221
  19. Heald-Sargent T, Gallagher T. Ready, set, fuse! The coronavirus spike protein and acquisition of fusion competence. Viruses 2012; 4(4): 557-80. doi: 10.3390/v4040557 PMID: 22590686
  20. Li F. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol 2016; 3(1): 237-61. doi: 10.1146/annurev-virology-110615-042301 PMID: 27578435
  21. Hulswit RJG, de Haan CAM, Bosch BJ. Coronavirus spike protein and tropism changes. Adv Virus Res 2016; 96: 29-57. doi: 10.1016/bs.aivir.2016.08.004 PMID: 27712627
  22. Xu Y, Lou Z, Liu Y, et al. Crystal structure of severe acute respiratory syndrome coronavirus spike protein fusion core. J Biol Chem 2004; 279(47): 49414-9. doi: 10.1074/jbc.M408782200 PMID: 15345712
  23. Post-COVID-19 global health strategies: The need for an interdisciplinary approach. Aging Clin Exp Res 2020; 32(8): 1613-20.
  24. Yen BL, Yen ML, Wang LT, Liu KJ, Sytwu HK. Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID-19. Stem Cells Transl Med 2020; 9(10): 1163-73. doi: 10.1002/sctm.20-0186 PMID: 32526079
  25. Zendedel E, Atkin SL, Sahebkar A. Use of stem cells as carriers of oncolytic viruses for cancer treatment. J Cell Physiol 2019; 234(9): 14906-13. doi: 10.1002/jcp.28320 PMID: 30770550
  26. Lee BC, Kang KS. Functional enhancement strategies for immunomodulation of mesenchymal stem cells and their therapeutic application. Stem Cell Res Ther 2020; 11(1): 397. doi: 10.1186/s13287-020-01920-3 PMID: 32928306
  27. Moll G, Drzeniek N, Kamhieh-Milz J, Geissler S, Volk HD, Reinke P. MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy. Front Immunol 2020; 11: 1091. doi: 10.3389/fimmu.2020.01091 PMID: 32574263
  28. Shetty AK. Mesenchymal stem cell infusion shows promise for combating coronavirus (COVID-19)-induced pneumonia. Aging Dis 2020; 11(2): 462-4. doi: 10.14336/AD.2020.0301 PMID: 32257554
  29. Öztürk S, Elçin AE, Elçin YM. Mesenchymal Stem Cells for Coronavirus (COVID-19)-Induced Pneumonia: Revisiting the Paracrine Hypothesis with New Hopes? Aging Dis 2020; 11(3): 477-9. doi: 10.14336/AD.2020.0403 PMID: 32489694
  30. Chen L, Qu J, Kalyani FS, et al. Mesenchymal stem cell-based treatments for COVID-19: Status and future perspectives for clinical applications. Cell Mol Life Sci 2022; 79(3): 142. doi: 10.1007/s00018-021-04096-y PMID: 35187617
  31. Csobonyeiova M, Smolinska V, Harsanyi S, Ivantysyn M, Klein M. The Immunomodulatory Role of Cell-Free Approaches in SARS-CoV-2-Induced Cytokine Storm—A Powerful Therapeutic Tool for COVID-19 Patients. Biomedicines 2023; 11(6): 1736. doi: 10.3390/biomedicines11061736 PMID: 37371831
  32. Kandula UR, Wake AD. Effectiveness of RCTs Pooling Evidence on Mesenchymal Stem Cell (MSC) Therapeutic Applications During COVID-19 Epidemic: A Systematic Review. Biologics 2023; 17: 85-112. PMID: 37223116
  33. Zarrabi M, Shahrbaf MA, Nouri M, et al. Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: A randomized controlled trial. Stem Cell Res Ther 2023; 14(1): 169. doi: 10.1186/s13287-023-03402-8 PMID: 37365605
  34. Taufiq H, Shaik Fakiruddin K, Muzaffar U, et al. Systematic review and meta-analysis of mesenchymal stromal/stem cells as strategical means for the treatment of COVID-19. Ther Adv Respir Dis 2023; 17. doi: 10.1177/17534666231158276 PMID: 37128999
  35. Liu Q, Ma F, Zhong Y, et al. Efficacy and safety of human umbilical cord-derived mesenchymal stem cells for COVID-19 pneumonia: A meta-analysis of randomized controlled trials. Stem Cell Res Ther 2023; 14(1): 118. doi: 10.1186/s13287-023-03286-8 PMID: 37143167
  36. Feng Y. Application of MSCs therapy in COVID-19. Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022).
  37. Norouzi-Barough L, Asgari Khosroshahi A, Gorji A, Zafari F, Shahverdi Shahraki M, Shirian S. COVID-19-induced stroke and the potential of using mesenchymal stem cells-derived extracellular vesicles in the regulation of neuroinflammation. Cell Mol Neurobiol 2023; 43(1): 37-46. doi: 10.1007/s10571-021-01169-1 PMID: 35025001
  38. Chakraborty R, Parvez S. COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials. Biochem Pharmacol 2020; 180: 114184. doi: 10.1016/j.bcp.2020.114184 PMID: 32739342
  39. Alzahrani FA. The Potential Use of Mesenchymal Stem Cells and Their Derived Exosomes as Immunomodulatory Agents for COVID-19 Patients. Stem Cells Int 2020; 2020: 8835986.
  40. Woods N, MacLoughlin R. Defining a Regulatory Strategy for ATMP/Aerosol Delivery Device Combinations in the Treatment of Respiratory Disease. Pharmaceutics 2020; 12(10): 922. doi: 10.3390/pharmaceutics12100922 PMID: 32993197
  41. Brave H, MacLoughlin R. State of the Art Review of Cell Therapy in the Treatment of Lung Disease, and the Potential for Aerosol Delivery. Int J Mol Sci 2020; 21(17): 6435. doi: 10.3390/ijms21176435 PMID: 32899381
  42. O’Driscoll L. Extracellular vesicles from mesenchymal stem cells as a Covid-19 treatment. Drug Discov Today 2020; 25(7): 1124-5. doi: 10.1016/j.drudis.2020.04.022 PMID: 32387262
  43. Raza SS, Khan MA. Mesenchymal stem cells: A new front emerges in coronavirus disease 2019 treatment. Cytotherapy 2022; 24(8): 755-66. doi: 10.1016/j.jcyt.2020.07.002 PMID: 35880307
  44. Lu L. The "Salmon Spirit" of translational medical research. Ann Transl Med 2020; 8(8): 560. doi: 10.21037/atm.2020.04.29 PMID: 32775361
  45. Meng F, Xu R, Wang S, et al. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: A phase 1 clinical trial. Signal Transduct Target Ther 2020; 5(1): 172. doi: 10.1038/s41392-020-00286-5 PMID: 32855385
  46. Irmak DK, Darıcı H, Karaöz E. Stem cell based therapy option in COVID-19: Is it really promising? Aging Dis 2020; 11(5): 1174-91. doi: 10.14336/AD.2020.0608 PMID: 33014531
  47. Sleem A, Saleh F. Mesenchymal stem cells in the fight against viruses: Face to face with the invisible enemy. Curr Res Transl Med 2020; 68(3): 105-10. doi: 10.1016/j.retram.2020.04.003 PMID: 32616467
  48. Choudhery MS, Harris DT. Stem cell therapy for COVID-19: Possibilities and challenges. Cell Biol Int 2020; 44(11): 2182-91. doi: 10.1002/cbin.11440 PMID: 32767687
  49. Wang XY. MSCs transplantation may be a potential therapeutic strategy for COVID-19 treatment. Eur Rev Med Pharmacol Sci 2020; 24(8): 4537-8. PMID: 32373992
  50. Khorshidi M, Zarezadeh M, Emami M, Olang B, Moradi Moghaddam O. Promising impacts of mesenchymal stem cell therapy in treatment of SARS-CoV-2 (COVID-19). Heart Lung 2020; 49(6): 745-8. doi: 10.1016/j.hrtlng.2020.08.007 PMID: 32911459
  51. Mirmotalebisohi SA, et al. Identification of the crucial regulatory elements modulating the host respiratory response to SARS-CoV-2 using motif detection, A systems biology approach. Regeneration. Reconstruction & Restoration 2020; 5(1): 4.
  52. Rad MR. Effect of vitamin K2 as a stimulants of bone regeneration in osteoporosis therapy. Regen Reconstr Restor 2020; 5(1): 5.
  53. Bamba C, Singh SP, Choudhury S. Can mesenchymal stem cell therapy be the interim management of COVID-19? Drug Discov Ther 2020; 14(3): 139-42. doi: 10.5582/ddt.2020.03032 PMID: 32554953
  54. Sadeghi S, Soudi S, Shafiee A, Hashemi SM. Mesenchymal stem cell therapies for COVID-19: Current status and mechanism of action. Life Sci 2020; 262: 118493. doi: 10.1016/j.lfs.2020.118493 PMID: 32979360
  55. Smith JA. Proliferation of mesenchymal stem cell trials for COVID-19: Risks and recommendations. 2020. Available from: https:///C:/Users/Bisma/Downloads/2020.04.21%20MSC%20trial%20preprint.pdf
  56. Lythgoe MP, Middleton P. Ongoing clinical trials for the management of the COVID-19 pandemic. Trends Pharmacol Sci 2020; 41(6): 363-82. doi: 10.1016/j.tips.2020.03.006 PMID: 32291112
  57. Erol ÖD, Aerts-Kaya F. Use of Mesenchymal Stem Cells in COVID-19. 2020. Available from:https://www.ishworld.org/ishData/userfiles/file/ISH-WEBSITE-COVID-19-and-HEMATOLOGY-SERIES-Fatima-Aerts-and-Ozgur-Dogus-Erol-Use-of-MSCs-in-COVID-Review-10-Haziran-2020.pdf
  58. Al-Anazi K, Al-Jasser A. The rising role of mesenchymal stem cells in the treatment of COVID-19 infections. J Stem Cell Ther Transplant 2020; 4: 011-6. doi: 10.29328/journal.jsctt.1001021
  59. Zumla A, Wang FS, Ippolito G, et al. Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy — Achieving global consensus and visibility for cellular host-directed therapies. Int J Infect Dis 2020; 96: 431-9. doi: 10.1016/j.ijid.2020.05.040 PMID: 32425638
  60. Ardura M, Hartley D, Dandoy C, Lehmann L, Jaglowski S, Auletta JJ. Addressing the impact of the Coronavirus Disease (COVID-19) pandemic on hematopoietic cell transplantation: Learning networks as means for sharing best practices. Biol Blood Marrow Transplant 2020; 26(7): e147-60. doi: 10.1016/j.bbmt.2020.04.018 PMID: 32339662
  61. Chibber P, Haq SA, Ahmed I, Andrabi NI, Singh G. Advances in the possible treatment of COVID-19: A review. Eur J Pharmacol 2020; 883: 173372. doi: 10.1016/j.ejphar.2020.173372 PMID: 32682787
  62. Hamdan H, Hashmi SK, Lazarus H, Gale RP, Qu W, El Fakih R. Promising role for mesenchymal stromal cells in coronavirus infectious disease-19 (COVID-19)-related severe acute respiratory syndrome? Blood Rev 2021; 46: 100742. doi: 10.1016/j.blre.2020.100742 PMID: 32854985
  63. Wang X, Wang H, Lu J, et al. Erythropoietin-Modified Mesenchymal Stem Cells Enhance Anti-fibrosis Efficacy in Mouse Liver Fibrosis Model. Tissue Eng Regen Med 2020; 17(5): 683-93. doi: 10.1007/s13770-020-00276-2 PMID: 32621283
  64. Hajivalili M, Hosseini M, Haji-Fatahaliha M. Gaining insights on immune responses to the novel coronavirus, COVID-19 and therapeutic challenges. Life Sci 2020; 257: 118058. doi: 10.1016/j.lfs.2020.118058 PMID: 32653518
  65. Peng M. Outbreak of COVID-19: An emerging global pandemic threat. Biomed Pharmacother 2020; 129: 110499. doi: 10.1016/j.biopha.2020.110499 PMID: 32768974
  66. Tu YF, Chien CS, Yarmishyn AA, et al. A review of SARS-CoV-2 and the ongoing clinical trials. Int J Mol Sci 2020; 21(7): 2657. doi: 10.3390/ijms21072657 PMID: 32290293
  67. Das M, et al. COVID-19 neurotropism and implications for therapy. Neuroimmunol Neuroinflamm 2020; 7(2): 141-9.
  68. Sahu KK, Siddiqui AD, Cerny J. Mesenchymal Stem Cells in COVID-19: A Journey from Bench to Bedside. Lab Med 2021; 52(1): 24-35. doi: 10.1093/labmed/lmaa049 PMID: 32729620
  69. Villarta-De Dios NP, Osio-Salido ES. Should Mesenchymal Stem Cell Therapy be used in the treatment of COVID-19? Acta Med Philipp 2020; 54.
  70. Yadav P, Vats R, Bano A, Bhardwaj R. Mesenchymal stem cell immunomodulation and regeneration therapeutics as an ameliorative approach for COVID-19 pandemics. Life Sci 2020; 263: 118588. doi: 10.1016/j.lfs.2020.118588 PMID: 33049279
  71. Gosain R, Abdou Y, Singh A, Rana N, Puzanov I, Ernstoff MS. COVID-19 and cancer: A comprehensive review. Curr Oncol Rep 2020; 22(5): 53. doi: 10.1007/s11912-020-00934-7 PMID: 32385672
  72. Chatterjee V, Yang X, Ma Y, Wu MH, Yuan SY. Extracellular vesicles: New players in regulating vascular barrier function. Am J Physiol Heart Circ Physiol 2020; 319(6): H1181-96. doi: 10.1152/ajpheart.00579.2020 PMID: 33035434
  73. Rodriguez HC, Gupta M, Cavazos-Escobar E, El-Amin SF III, Gupta A. Umbilical cord: An allogenic tissue for potential treatment of COVID-19. Hum Cell 2021; 34(1): 1-13. doi: 10.1007/s13577-020-00444-5 PMID: 33033884
  74. Mallis P, Michalopoulos E, Chatzistamatiou T, Stavropoulos-Giokas C. Mesenchymal stromal cells as potential immunomodulatory players in severe acute respiratory distress syndrome induced by SARS-CoV-2 infection. World J Stem Cells 2020; 12(8): 731-51. doi: 10.4252/wjsc.v12.i8.731 PMID: 32952855
  75. Mahajan A, Bhattacharyya S. Application of Mesenchymal stem celland secretome for combating mortality and morbidity in COVID-19patients: A brief review. Biomed J 2020.
  76. Sohag AAM, Hannan MA, Rahman S, et al. Revisiting potential druggable targets against SARS-CoV -2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review. Drug Dev Res 2020; 81(8): 919-41. doi: 10.1002/ddr.21709 PMID: 32632960
  77. Can A, Coskun H. The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect. Stem Cells Transl Med 2020; 9(11): 1287-302. doi: 10.1002/sctm.20-0164 PMID: 32779878
  78. Louchet M, Sibiude J, Peytavin G, Picone O, Tréluyer JM, Mandelbrot L. Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019. Am J Obstet Gynecol MFM 2020; 2(3): 100159. doi: 10.1016/j.ajogmf.2020.100159 PMID: 32838264
  79. Khadke S, Ahmed N, Ahmed N, et al. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents. Virol J 2020; 17(1): 1-8.
  80. Geng YJ, Wei ZY, Qian HY, Huang J, Lodato R, Castriotta RJ. Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019. Cardiovasc Pathol 2020; 47: 107228. doi: 10.1016/j.carpath.2020.107228 PMID: 32375085
  81. Bhandari R, Khanna G, Kuhad A. Pharmacological insight into potential therapeutic agents for the deadly Covid-19 pandemic. Eur J Pharmacol 2021; 890: 173643. doi: 10.1016/j.ejphar.2020.173643 PMID: 33065092
  82. Jayaramayya K, Mahalaxmi I, Subramaniam MD, et al. Immunomodulatory effect of mesenchymal stem cells and mesenchymal stem-cell-derived exosomes for COVID-19 treatment. BMB Rep 2020; 53(8): 400-12. doi: 10.5483/BMBRep.2020.53.8.121 PMID: 32731913
  83. Pujari R, Thommana MV, Ruiz Mercedes B, Serwat A. Therapeutic Options for COVID-19: A Review. Cureus 2020; 12(9): e10480. PMID: 32953365
  84. Lotfi M, Hamblin MR, Rezaei N. COVID-19: Transmission, prevention, and potential therapeutic opportunities. Clin Chim Acta 2020; 508: 254-66. doi: 10.1016/j.cca.2020.05.044 PMID: 32474009
  85. Ulm JW, Nelson SF. COVID-19 drug repurposing: Summary statistics on current clinical trials and promising untested candidates. Transbound Emerg Dis 2021; 68(2): 313-7. doi: 10.1111/tbed.13710 PMID: 32619318
  86. Lechowicz K, Drożdżal S, Machaj F, et al. COVID-19: the potential treatment of pulmonary fibrosis associated with SARS-CoV-2 infection. J Clin Med 2020; 9(6): 1917. doi: 10.3390/jcm9061917 PMID: 32575380
  87. Almasi F, Mohammadipanah F. Hypothetical targets and plausible drugs of coronavirus infection caused by SARS-CoV-2. Transbound Emerg Dis 2021; 68(2): 318-32. doi: 10.1111/tbed.13734 PMID: 32662203
  88. Almasi F, Mohammadipanah F. Potential targets and plausible drugs of Coronavirus infection caused by 2019-nCoV. Authorea 2020.
  89. Sheervalilou R, Shirvaliloo M, Dadashzadeh N, et al. COVID-19 under spotlight: A close look at the origin, transmission, diagnosis, and treatment of the 2019-nCoV disease. J Cell Physiol 2020; 235(12): 8873-924. doi: 10.1002/jcp.29735 PMID: 32452539
  90. Oroojalian F, Haghbin A, Baradaran B, et al. Novel insights into the treatment of SARS-CoV-2 infection: An overview of current clinical trials. Int J Biol Macromol 2020; 165(Pt A): 18-43. doi: 10.1016/j.ijbiomac.2020.09.204 PMID: 32991900
  91. Yamamoto V, Bolanos JF, Fiallos J, et al. COVID-19: review of a 21st century pandemic from etiology to neuro-psychiatric implications. J Alzheimers Dis 2020; 77(2): 459-504. doi: 10.3233/JAD-200831 PMID: 32925078
  92. Teymoori-Rad M, Marashi SM, Vitamin D. Vitamin D and Covid-19: From potential therapeutic effects to unanswered questions. Rev Med Virol 2020; e2159.
  93. Benskin LL. A Basic Review of the Preliminary Evidence That COVID-19 Risk and Severity Is Increased in Vitamin D Deficiency. Front Public Health 2020; 8: 513. doi: 10.3389/fpubh.2020.00513 PMID: 33014983
  94. Song N, Wakimoto H, Rossignoli F, et al. Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm. Stem Cells 2021; 39(6): 707-22. doi: 10.1002/stem.3354 PMID: 33586320
  95. Shahani P, Datta I. Mesenchymal stromal cell therapy for coronavirus disease 2019: which? when? and how much? Cytotherapy 2021; 23(10): 861-73. doi: 10.1016/j.jcyt.2021.04.004 PMID: 34053857
  96. Ye Q, Wang H, Xia X, et al. Safety and efficacy assessment of allogeneic human dental pulp stem cells to treat patients with severe COVID-19: structured summary of a study protocol for a randomized controlled trial (Phase I/II). Trials 2020; 21(1): 520. doi: 10.1186/s13063-020-04380-5 PMID: 32532356
  97. Iannaccone G, Scacciavillani R, Del Buono MG, et al. Weathering the cytokine storm in COVID-19: therapeutic implications. Cardiorenal Med 2020; 10(5): 277-87. doi: 10.1159/000509483 PMID: 32599589
  98. Bahrami A, Ferns GA. Genetic and pathogenic characterization of SARS-CoV-2: a review. Future Virol 2020; 15(8): 533-49. doi: 10.2217/fvl-2020-0129
  99. Deev R. Cell transplantation in a COVID-19 treatment program: stem stromal (mesenchymal) cell transplantation. Genes Cells 2020; 15(2)
  100. Kothari A, Singh V, Nath UK, et al. Immune Dysfunction and Multiple Treatment Modalities for the SARS-CoV-2 Pandemic: Races of Uncontrolled Running Sweat? Biology (Basel) 2020; 9(9): 243. doi: 10.3390/biology9090243 PMID: 32846906
  101. Lisi L, Lacal PM, Barbaccia ML, Graziani G. Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2. Biochem Pharmacol 2020; 180: 114169. doi: 10.1016/j.bcp.2020.114169 PMID: 32710969
  102. Shweta F, et al. Augmented curation of unstructured clinical notes from a massive EHR system reveals specific phenotypic signature of impending COVID-19 diagnosis. arXiv 2020; 2020: 09338.
  103. Andrade KRC, Carvalho VKDS, Farinasso CM, et al. Pharmacological therapies for patients with human coronavirus infections: a rapid systematic review. Cien Saude Colet 2020; 25(9): 3517-54. doi: 10.1590/1413-81232020259.14242020 PMID: 32876256
  104. Ngo BT, Rendell M. A systematic analysis of the time course to develop treatments for covid-19. MedRxiv 2020.
  105. Andrade KRC, Carvalho VKS, Farinasso CM, et al. Terapia medicamentosa para infecções por coronavírus em humanos: revisão sistemática rápida. Cien Saude Colet 2020; 25(9): 3517-54. doi: 10.1590/1413-81232020259.14242020 PMID: 32876256
  106. Ngo BT. The time course of therapeutic interventions for COVID-19. medRxiv 2020; 2020
  107. Zhu Y, Zhu R, Liu K, et al. Human Umbilical Cord Mesenchymal Stem Cells for Adjuvant Treatment of a Critically Ill COVID-19 Patient: A Case Report. Infect Drug Resist 2020; 13: 3295-300. doi: 10.2147/IDR.S272645 PMID: 33061476
  108. Meacci E, Garcia-Gil M, Pierucci F. SARS-CoV-2 Infection: A Role for S1P/S1P Receptor Signaling in the Nervous System? Int J Mol Sci 2020; 21(18): 6773. doi: 10.3390/ijms21186773 PMID: 32942748
  109. López-Collazo E, Avendaño-Ortiz J, Martín-Quirós A, Aguirre LA. Immune Response and COVID-19: A mirror image of Sepsis. Int J Biol Sci 2020; 16(14): 2479-89. doi: 10.7150/ijbs.48400 PMID: 32792851
  110. Pandey A, Nikam AN, Shreya AB, et al. Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements. Life Sci 2020; 256: 117883. doi: 10.1016/j.lfs.2020.117883 PMID: 32497632
  111. Scarabel L, Guardascione M, Dal Bo M, Toffoli G. Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19. Int J Infect Dis 2021; 104: 441-51. doi: 10.1016/j.ijid.2021.01.035 PMID: 33476760
  112. Pakzad M, Hassani SN, Abbasi F, et al. A roadmap for the production of a GMP-compatible cell bank of allogeneic bone marrow-derived clonal mesenchymal stromal cells for cell therapy applications. Stem Cell Rev Rep 2022; 18(7): 2279-95. doi: 10.1007/s12015-022-10351-x PMID: 35175538
  113. Abu-El-Rub E, Khasawneh RR, Almahasneh F, et al. Mesenchymal stem cells and COVID-19: What they do and what they can do. World J Stem Cells 2021; 13(9): 1318-37. doi: 10.4252/wjsc.v13.i9.1318 PMID: 34630865
  114. Sharma Y, Rao EP, Mohanty S. An insight into the molecular mechanisms of mesenchymal stem cells and their translational approaches to combat COVID-19. Stem Cells 2022; COVID-19: 23-46.
  115. Patel M. Nanotechnology and stem cell therapy for combating COVID-19. Nanotechnology and Regenerative Medicine. 2023; pp. 155-77. doi: 10.1016/B978-0-323-90471-1.00013-X
  116. Jeyaraman M, John A, Koshy S, et al. Fostering mesenchymal stem cell therapy to halt cytokine storm in COVID-19. Biochim Biophys Acta Mol Basis Dis 2021; 1867(2): 166014. doi: 10.1016/j.bbadis.2020.166014 PMID: 33232817
  117. Esmaeilzadeh A, Elahi R. Immunobiology and immunotherapy of COVID-19: A clinically updated overview. J Cell Physiol 2021; 236(4): 2519-43. doi: 10.1002/jcp.30076 PMID: 33022076
  118. Zaki MM, Lesha E, Said K, et al. Cell therapy strategies for COVID-19: Current approaches and potential applications. Sci Adv 2021; 7(33): eabg5995. doi: 10.1126/sciadv.abg5995 PMID: 34380619
  119. Siemieniuk RA. Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. BMJ 2021; 374: n2231.
  120. Widowati W, Faried A, Kusuma HSW, Hermanto Y, Harsono AB, Djuwantono T. Allogeneic Mesenchymal Stem Cells and Its Conditioned Medium as a Potential Adjuvant Therapy for COVID-19. Molecular and Cellular Biomedical Sciences 2023; 7(1): 1-9. doi: 10.21705/mcbs.v7i1.287
  121. Dilogo IH, Aditianingsih D, Sugiarto A, et al. Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: A randomized controlled trial. Stem Cells Transl Med 2021; 10(9): 1279-87. doi: 10.1002/sctm.21-0046 PMID: 34102020
  122. Moloudizargari M, Govahi A, Fallah M, Rezvanfar MA, Asghari MH, Abdollahi M. The mechanisms of cellular crosstalk between mesenchymal stem cells and natural killer cells: Therapeutic implications. J Cell Physiol 2021; 236(4): 2413-29. doi: 10.1002/jcp.30038 PMID: 32892356
  123. Wang L, et al. Stem Cell Res (Amst) 2020; •••: 101985.
  124. Saldanha-Araujo F, Melgaço Garcez E, Silva-Carvalho AE, Carvalho JL. Mesenchymal Stem Cells: A New Piece in the Puzzle of COVID-19 Treatment. Front Immunol 2020; 11: 1563. doi: 10.3389/fimmu.2020.01563 PMID: 32719683
  125. Vivarelli S, Falzone L, Grillo CM, Scandurra G, Torino F, Libra M. Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial? Cancers (Basel) 2020; 12(8): 2237. doi: 10.3390/cancers12082237 PMID: 32785162
  126. Baindara P, Agrawal S, Mandal SM. Host-directed therapies: a potential solution to combat COVID-19. Expert Opin Biol Ther 2020; 20(10): 1117-20. doi: 10.1080/14712598.2020.1807001 PMID: 32783643
  127. Ma MT, et al. Efficacy of Targeting SARS-CoV-2 by CAR-NK Cells. bioRxiv 2020; 2020-08. doi: 10.1101/2020.08.11.247320
  128. Market M, Angka L, Martel AB, et al. Flattening the COVID-19 curve with natural killer cell based immunotherapies. Front Immunol 2020; 11: 1512. doi: 10.3389/fimmu.2020.01512 PMID: 32655581
  129. Pashaei M, Rezaei N. Immunotherapy for SARS-CoV-2: potential opportunities. Expert Opin Biol Ther 2020; 20(10): 1111-6. doi: 10.1080/14712598.2020.1807933 PMID: 32762581
  130. Fouladseresht H, Doroudchi M, Rokhtabnak N, et al. Predictive monitoring and therapeutic immune biomarkers in the management of clinical complications of COVID-19. Cytokine Growth Factor Rev 2021; 58: 32-48. doi: 10.1016/j.cytogfr.2020.10.002 PMID: 33199179
  131. Sarkar C, Mondal M, Torequl Islam M, et al. Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives. Front Pharmacol 2020; 11: 572870. doi: 10.3389/fphar.2020.572870 PMID: 33041814
  132. Manickam C, Sugawara S, Reeves RK. Friends or foes? The knowns and unknowns of natural killer cell biology in COVID-19 and other coronaviruses in July 2020. PLoS Pathog 2020; 16(8): e1008820. doi: 10.1371/journal.ppat.1008820 PMID: 32845937
  133. Leyfman Y, Erick TK, Reddy SS, et al. Potential immunotherapeutic targets for hypoxia due to COVI-FLU. Shock 2020; 54(4): 438-50. doi: 10.1097/SHK.0000000000001627 PMID: 32649367
  134. Feng Y, Huang J, Wu J, et al. Safety and feasibility of umbilical cord mesenchymal stem cells in patients with COVID-19 pneumonia: A pilot study. Cell Prolif 2020; 53(12): e12947. doi: 10.1111/cpr.12947 PMID: 33205469
  135. Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun 2020; 111: 102452. doi: 10.1016/j.jaut.2020.102452 PMID: 32291137
  136. Bhagavathula AS, Aldhaleei W, Rovetta A, Rahmani J. Vaccines and Drug Therapeutics to Lock Down Novel Coronavirus Disease 2019 (COVID-19): A Systematic Review of Clinical Trials. Cureus 2020; 12(5): e8342. doi: 10.7759/cureus.8342 PMID: 32494546
  137. Sahu KK, Mishra AK, Lal A. Comprehensive update on current outbreak of novel coronavirus infection (2019-nCoV). Ann Transl Med 2020; 8(6): 393. doi: 10.21037/atm.2020.02.92 PMID: 32355837
  138. Shafiee A, Moradi L, Lim M, Brown J. Coronavirus disease 2019: A tissue engineering and regenerative medicine perspective. Stem Cells Trans Med 2019; 10(1): 27-38.
  139. Karami A. A Summary of Effective Management of COVID-19 in Iran Collaboration of Civil and Defense forces. CBW Magazine 2020; 13.(2)
  140. Atluri S, Manchikanti L, Hirsch JA. H. is Vice, and L. Manchikanti, Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically ill COVID-19 patients: the case for compassionate use. Pain Physician 2020; 23(2): E71-83. PMID: 32214286
  141. Singh VK, Mishra A, Singh S, et al. Emerging prevention and treatment strategies to control COVID-19. Pathogens 2020; 9(6): 501. doi: 10.3390/pathogens9060501 PMID: 32585805
  142. Deshmukh V. COVID-19: A conundrum to decipher. Eur Rev Med Pharmacol Sci 2020; 24(10): 5830-41.
  143. DE EVIDÊNCIAS SDP. Rapid review of therapeutic alternatives for Human Coronavirus: update. . Virtual Health Library 2020.
  144. Qiu R, et al. Outcome reporting from protocols of clinical trials of Coronavirus Disease 2019 (COVID-19): A review. medRxiv 2020; 2020-03. doi: 10.1101/2020.03.04.20031401
  145. Mallikarjuna C. Coronavirus-Bibliography. IITHLibrary 2020.
  146. Maron BA, Gladwin MT, Bonnet S, et al. Perspectives on Cardiopulmonary Critical Care for Patients With COVID-19: From Members of the American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation. J Am Heart Assoc 2020; 9(14): e017111. doi: 10.1161/JAHA.120.017111 PMID: 32552164
  147. Gorman E, Shankar-Hari M, Hopkins P, et al. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial. Trials 2020; 21(1): 462. doi: 10.1186/s13063-020-04416-w PMID: 32493473
  148. Banking CB, Blood C, Works HI. Could umbilical cord stem cells help treat patients with Coronavirus (COVID-19)?. Blue print biobank 2020.
  149. Raza SS, Seth P, Khan MA. ‘Primed’Mesenchymal Stem Cells: a Potential Novel Therapeutic for COVID19 Patients. Stem Cell Rev Rep 2020; 1-10. PMID: 32592163
  150. Abraham A, Krasnodembskaya A. Mesenchymal stem cell-derived extracellular vesicles for the treatment of acute respiratory distress syndrome. Stem Cells Transl Med 2020; 9(1): 28-38. doi: 10.1002/sctm.19-0205 PMID: 31647191
  151. Horie S, McNicholas B, Rezoagli E, et al. Emerging pharmacological therapies for ARDS: COVID-19 and beyond. Intensive Care Med 2020; 46(12): 2265-83. doi: 10.1007/s00134-020-06141-z PMID: 32654006
  152. Millar JE, von Bahr V, Malfertheiner MV, et al. Administration of mesenchymal stem cells during ECMO results in a rapid decline in oxygenator performance. Thorax 2019; 74(2): 194-6. doi: 10.1136/thoraxjnl-2017-211439 PMID: 29622695
  153. Cruz FF, Rocco PRM. Cell therapy for acute respiratory distress syndrome patients: the START study. J Thorac Dis 2019; 11(S9) (Suppl. 9): S1329-32. doi: 10.21037/jtd.2019.04.22 PMID: 31245124
  154. Han J, Liu Y, Liu H, Li Y. Genetically modified mesenchymal stem cell therapy for acute respiratory distress syndrome. Stem Cell Res Ther 2019; 10(1): 386. doi: 10.1186/s13287-019-1518-0 PMID: 31843004
  155. Boyle AJ, O’Kane CM, McAuley DF. Where next for cell-based therapy in ARDS. Thorax 2019; 74(1): 13-5. doi: 10.1136/thoraxjnl-2018-212272 PMID: 30420408
  156. Hussain M, Xu C, Ahmad M, et al. Acute respiratory distress syndrome: bench-to-bedside approaches to improve drug development. Clin Pharmacol Ther 2018; 104(3): 484-94. doi: 10.1002/cpt.1034 PMID: 29484641
  157. Laffey JG, Matthay MA. Fifty years of research in ARDS. Cell-based therapy for acute respiratory distress syndrome. Biology and potential therapeutic value. Am J Respir Crit Care Med 2017; 196(3): 266-73. doi: 10.1164/rccm.201701-0107CP PMID: 28306336
  158. Chrzanowski W, Kim SY, McClements L. Can Stem Cells Beat COVID-19: Advancing Stem Cells and Extracellular Vesicles Toward Mainstream Medicine for Lung Injuries Associated With SARS-CoV-2 Infections. Front Bioeng Biotechnol 2020; 8: 554. doi: 10.3389/fbioe.2020.00554 PMID: 32574317
  159. Amann EM. Immunomodulatory and regenerative effects of mesenchymal stromal cells in trauma. Doctoral dissertation, Universität Ulm 2019.
  160. Guillamat-Prats R, Camprubí-Rimblas M, Bringué J, Tantinyà N, Artigas A. Cell therapy for the treatment of sepsis and acute respiratory distress syndrome. Ann Transl Med 2017; 5(22): 446. doi: 10.21037/atm.2017.08.28 PMID: 29264363
  161. Robinson MJ, Krasnodembskaya AD. Therapeutic targeting of metabolic alterations in acute respiratory distress syndrome. Eur Respir Rev 2020; 29(156): 200114. doi: 10.1183/16000617.0114-2020 PMID: 32620587
  162. Matthay MA, McAuley DF, Ware LB. Clinical trials in acute respiratory distress syndrome: challenges and opportunities. Lancet Respir Med 2017; 5(6): 524-34. doi: 10.1016/S2213-2600(17)30188-1 PMID: 28664851
  163. Horie S, Gonzalez HE, Laffey JG, Masterson CH. Cell therapy in acute respiratory distress syndrome. J Thorac Dis 2018; 10(9): 5607-20. doi: 10.21037/jtd.2018.08.28 PMID: 30416812
  164. Shaw TD, McAuley DF, O’Kane CM. Emerging drugs for treating the acute respiratory distress syndrome. Expert Opin Emerg Drugs 2019; 24(1): 29-41. doi: 10.1080/14728214.2019.1591369 PMID: 30841764
  165. Laroye C, Gibot S, Reppel L, Bensoussan D. Concise review: mesenchymal stromal/stem cells: a new treatment for sepsis and septic shock? Stem Cells 2017; 35(12): 2331-9. doi: 10.1002/stem.2695 PMID: 28856759
  166. Patry C, Doniga T, Lenz F, et al. Increased mobilization of mesenchymal stem cells in patients with acute respiratory distress syndrome undergoing extracorporeal membrane oxygenation. PLoS One 2020; 15(1): e0227460. doi: 10.1371/journal.pone.0227460 PMID: 31986159
  167. Lian J, Lin J, Zakaria N, Yahaya BH. Acute lung injury: Disease modelling and the therapeutic potential of stem cells. In: Cell Biology and Translational Medicine. . Cham: Springer 2020; 10: pp. 149-66.
  168. Rezoagli E. The Safety and Efficiency of Addressing ARDS Using Stem Cell Therapies in Clinical Trials. In: Stem Cell-Based Therapy for Lung Disease. Cham: Springer 2019; pp. 219-38. doi: 10.1007/978-3-030-29403-8_12
  169. Silva PL, Pelosi P, Rocco PRM. Personalized pharmacological therapy for ARDS: a light at the end of the tunnel. Expert Opin Investig Drugs 2020; 29(1): 49-61. doi: 10.1080/13543784.2020.1699531 PMID: 31778609
  170. Guillamat-Prats R, Artigas A. Current Status of Stem Cell Therapy for Sepsis and Acute Respiratory Distress Syndrome. In: Innovations in Cell Research and Therapy. IntechOpen 2019.
  171. Kyriazopoulou E, Giamarellos-Bourboulis EJ. Pharmacological management of sepsis in adults with a focus on the current gold standard treatments and promising adjunctive strategies: evidence from the last five years. Expert Opin Pharmacother 2019; 20(8): 991-1007. doi: 10.1080/14656566.2019.1589451 PMID: 30879348
  172. Vasudevan A, Mantan M, Krishnamurthy S, et al. Managing children with renal diseases during the COVID-19 pandemic. Indian Pediatr 2020; 57(7): 641-51. doi: 10.1007/s13312-020-1893-8 PMID: 32727941
  173. Lewis SR. Pharmacological agents for adults with acute respiratory distress syndrome. Cochrane Database Syst Rev 2019; 7(7): CD004477. doi: 10.1002/14651858.CD004477.pub3
  174. Rosenheck J, Pietras C, Cantu E. Early graft dysfunction after lung transplantation. Curr Pulmonol Rep 2018; 7(4): 176-87. doi: 10.1007/s13665-018-0213-4 PMID: 31548919
  175. Artigas A. 25th International Symposium on Infections in the Critically Ill. Patient Med Sci 2020; 8: 13.
  176. Homolak J, Kodvanj I. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19. Int J Antimicrob Agents 2020; 56(2): 106044. doi: 10.1016/j.ijantimicag.2020.106044 PMID: 32522674
  177. Lotfi M, Rezaei N. SARS-CoV-2: A comprehensive review from pathogenicity of the virus to clinical consequences. J Med Virol 2020; 92(10): 1864-74. doi: 10.1002/jmv.26123 PMID: 32492197
  178. Gentile P, Sterodimas A, Pizzicannella J, Calabrese C, Garcovich S. Research progress on Mesenchymal Stem Cells (MSCs), Adipose-Derived Mesenchymal Stem Cells (AD-MSCs), Drugs, and Vaccines in Inhibiting COVID-19 Disease. Aging Dis 2020; 11(5): 1191-201. doi: 10.14336/AD.2020.0711 PMID: 33014532
  179. Jeyaraman M, Somasundaram R, Anudeep TC, et al. Mesenchymal Stem Cells (MSCs) as a Novel Therapeutic Option for nCOVID-19—A Review. Open Journal of Regenerative Medicine 2020; 9(2): 20-35. doi: 10.4236/ojrm.2020.92004
  180. Jeyaraman M, Ranjan R, Kumar R, et al. Cellular therapy: shafts of light emerging for COVID-19. Stem Cell Investig 2020; 7: 11. doi: 10.21037/sci-2020-022 PMID: 32695804
  181. Özkan S, Koyutürk M. Covid-19 Hastalarında Mezenkimal Kök Hücre Tedavisi ve Yeni Yaklaşımlar. Cerrahpasa Medical Journal 2020; 44(2): 57-64. doi: 10.5152/cjm.2020.20017
  182. Pooladanda V, Thatikonda S, Godugu C. The current understanding and potential therapeutic options to combat COVID-19. Life Sci 2020; 254: 117765. doi: 10.1016/j.lfs.2020.117765 PMID: 32437797
  183. Tavakoli S, Ghaderi Jafarbeigloo HR, Shariati A, et al. Mesenchymal stromal cells; a new horizon in regenerative medicine. J Cell Physiol 2020; 235(12): 9185-210. doi: 10.1002/jcp.29803 PMID: 32452052
  184. Agrawal M, Saraf S, Saraf S, et al. In-line treatments and clinical initiatives to fight against COVID-19 outbreak. Respir Med 2022; 191: 106192. doi: 10.1016/j.rmed.2020.106192 PMID: 33199136
  185. Zhao RC. Stem Cell–Based Therapy for Coronavirus Disease 2019. Stem Cells Dev 2020; 29(11): 679-81. doi: 10.1089/scd.2020.0071 PMID: 32292113
  186. Rajarshi K, Chatterjee A, Ray S. Combating COVID-19 with mesenchymal stem cell therapy. Biotechnol Rep (Amst) 2020; 26: e00467. doi: 10.1016/j.btre.2020.e00467 PMID: 32420049
  187. Ghosh A. A review of mesenchymal stem cell therapy for severe SARS-CoV-2 infection. Praxis Undergraduate Medical Research Journal 2020.
  188. Ribeiro TB, et al. Iniciativas brasileiras de estudos de intervenção em andamento para a COVID-19. SciELO Preprints 2020.
  189. Sahu K, Kumar R. Preventive and treatment strategies of COVID-19: From community to clinical trials. J Family Med Prim Care 2020; 9(5): 2149-57. doi: 10.4103/jfmpc.jfmpc_728_20 PMID: 32754463
  190. Ahamad S, Branch S, Harrelson S, Hussain MK, Saquib M, Khan S. Primed for global coronavirus pandemic: Emerging research and clinical outcome. Eur J Med Chem 2021; 209: 112862. doi: 10.1016/j.ejmech.2020.112862 PMID: 33070079
  191. Ribeiro TB, Mazotti TA, Silva NAO, Stein AT, Diaz-Quijano FA, Melo DO. Avaliação da resposta inicial de desenvolvimento de ensaios clínicos para COVID-19 no Brasil. Rev Bras Epidemiol 2020; 23: e200104. doi: 10.1590/1980-549720200104
  192. Hossein-khannazer N, Shokoohian B, Shpichka A, Aghdaei HA, Timashev P, Vosough M. Novel therapeutic approaches for treatment of COVID-19. J Mol Med 2020; 98(6): 789-803. doi: 10.1007/s00109-020-01927-6 PMID: 32494931
  193. Baklaushev V, et al. COVID-19. Aetiology, pathogenesis, diagnosis and treatment. Journal of Clinical Practice 2020; 11(1): 7-20.
  194. Бaклayшeв BП, et al. COVID-19COVID-19. Etiology, pathogenesis, diagnosis and treatment. Clin Pract 2020; 11(1): 7-20.
  195. Song X, Hu W, Yu H, Zhao L, Zhao Y, Zhao Y. High expression of angiotensin-converting enzyme-2 (ACE2) on tissue macrophages that may be targeted by virus SARS-CoV-2 in COVID-19 patients. bioRxiv 2020; 2020-07. doi: 10.1101/2020.07.18.210120
  196. Wang J, Jiang M, Chen X, Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol 2020; 108(1): 17-41. doi: 10.1002/JLB.3COVR0520-272R PMID: 32534467
  197. Chakhalian D, Shultz RB, Miles CE, Kohn J. Opportunities for biomaterials to address the challenges of COVID -19. J Biomed Mater Res A 2020; 108(10): 1974-90. doi: 10.1002/jbm.a.37059 PMID: 32662571
  198. Solinas C, Perra L, Aiello M, Migliori E, Petrosillo N. A critical evaluation of glucocorticoids in the management of severe COVID-19. Cytokine Growth Factor Rev 2020; 54: 8-23. doi: 10.1016/j.cytogfr.2020.06.012 PMID: 32616381
  199. Monpara JD, Sodha SJ, Gupta PK. COVID-19 associated complications and potential therapeutic targets. Eur J Pharmacol 2020; 886: 173548. doi: 10.1016/j.ejphar.2020.173548 PMID: 32926918
  200. Oseltamivir no tratamento da cOVID-19. Revisão sistemática rápida 2020. Available from: https://oxfordbrazilebm.com/wp-content/uploads/2020/05/RS_rapida_oseltamivir_Covid_19.pdf
  201. Krawczenko A, Klimczak A. Adipose tissue-derived mesenchymal stem/stromal cells and their contribution to angiogenic processes in tissue regeneration. Int J Mol Sci 2022; 23(5): 2425. doi: 10.3390/ijms23052425 PMID: 35269568
  202. Li JP, Wu KH, Chao WR, Lee YJ, Yang SF, Chao YH. Immunomodulation of mesenchymal stem cells in acute lung injury: from preclinical animal models to treatment of severe COVID-19. Int J Mol Sci 2022; 23(15): 8196. doi: 10.3390/ijms23158196 PMID: 35897770
  203. Hao J. Stem cell therapy for COVID-19, ARDS and pulmonary fibrosis. Cell Prolif 2020; 53(12): e12939.
  204. Afarid M, Sanie-Jahromi F. Mesenchymal stem cells and COVID-19: Cure, prevention, and vaccination. Stem Cells Int 2021; 2021: 1-12. doi: 10.1155/2021/6666370 PMID: 34035820
  205. Dauletova M, Hafsan H, Mahhengam N, Zekiy AO, Ahmadi M, Siahmansouri H. Mesenchymal stem cell alongside exosomes as a novel cell-based therapy for COVID-19: A review study. Clin Immunol 2021; 226: 108712. doi: 10.1016/j.clim.2021.108712 PMID: 33684527
  206. Zambrano GMT. Stem cell nebulization therapy for COVID-19 infection: radiological and clinical outcomes. Egypt J Radiol Nucl Med 2021; 52(1): 1-11.
  207. Saburi E. The use of mesenchymal stem cells in the process of treatment and tissue regeneration after recovery in patients with Covid-19. Gene 2021; 777: 145471. doi: 10.1016/j.gene.2021.145471
  208. Rodriguez HC. Mesenchymal Stem Cells and Extracellular Vesicles: An Emerging Alternative to Combat COVID-19. intechopen 2021.
  209. Shi L, et al. Treatment with Human Umbilical Cord-Derived Mesenchymal Stem Cells for Severe COVID-19 Patients with Lung Damage: A Randomised, Double-Blind, Placebo-Controlled Phase 2 Trial. medrxiv 2020; 2020: 20213553.
  210. Lanzoni G. Umbilical Cord Mesenchymal Stem Cells for COVID-19 ARDS: A Double Blind, Phase 1/2a, Randomized Controlled Trial. Stem Cells Trans Med 2020; 10(5): 660-73.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers